Beyond the standard: Enhancing prostate bed and regional lymph node detection in prostate cancer patients with early and delayed imaging in [68 Ga]Ga-PSMA-11 PET/CT.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
38 patients, more than the ESI (n = 37) and DI (n = 24).
I · Intervention 중재 / 시술
routine [68 Ga]Ga-PSMA-11 PET/CT imaging, 4-minute static acquisition post-injection, and delayed imaging 3 h post-injection
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
[OBJECTIVES] This study aims to evaluate the diagnostic value of early static and delayed imaging in conjunction with standard 68Ga-PSMA-11 PET/CT scans to detect prostate malignant lesions in prostat
- 표본수 (n) 37
- p-value P < .001
APA
Aghaee A, Bakhshi Z, et al. (2026). Beyond the standard: Enhancing prostate bed and regional lymph node detection in prostate cancer patients with early and delayed imaging in [68 Ga]Ga-PSMA-11 PET/CT.. Revista espanola de medicina nuclear e imagen molecular, 45(1), 500184. https://doi.org/10.1016/j.remnie.2025.500184
MLA
Aghaee A, et al.. "Beyond the standard: Enhancing prostate bed and regional lymph node detection in prostate cancer patients with early and delayed imaging in [68 Ga]Ga-PSMA-11 PET/CT.." Revista espanola de medicina nuclear e imagen molecular, vol. 45, no. 1, 2026, pp. 500184.
PMID
40545162 ↗
Abstract 한글 요약
[OBJECTIVES] This study aims to evaluate the diagnostic value of early static and delayed imaging in conjunction with standard 68Ga-PSMA-11 PET/CT scans to detect prostate malignant lesions in prostate cancer patients.
[METHODS] One hundred and thirty-eight prostate cancer patients underwent routine [68 Ga]Ga-PSMA-11 PET/CT imaging, 4-minute static acquisition post-injection, and delayed imaging 3 h post-injection. The imaging results were analysed for lesion count, type, localisation, and maximum standardised uptake values.
[RESULTS] 57.97% exhibited positive findings for pathologic prostatic lesions in the standard PET scans (SUV: 10.24). In contrast, early PET imaging detected lesions in 58.01% of patients (SUV of 5.86), while delayed scans revealed lesions suggestive of malignancy in 55.45% of patients (SUV of 12.79). The analysis demonstrated a statistically significant difference in SUV values across the time points (P < .001). Pathologic lymph nodes on images 60 min p.i. were revealed by an SUV max 60 min p.i.: 15.78; this number for the first 4 min and after 3 h were 7.36, 19.19, respectively. Metastatic bone lesions on WB were found in 38 patients, more than the ESI (n = 37) and DI (n = 24). In comparison, urinary bladder activity assessment was detectable with the WB imaging SUV 60 min 11.07. Even though the SUV max for ESI and DI were 6.95 and 31.97, respectively. In the statistical analysis, pathologic radiotracer uptake in tumour lesions was statistically higher in ESI and WB than in urinary bladder activity.
[CONCLUSIONS] The findings indicate that neither early [68 Ga]Ga-PSMA-11 PET/CT nor delayed imaging significantly enhanced the overall detection rate of malignant lesions in prostate cancer patients. However, the early 4-minute post-injection acquisition of PET images proved beneficial for distinguishing local bladder invasion more effectively.
[METHODS] One hundred and thirty-eight prostate cancer patients underwent routine [68 Ga]Ga-PSMA-11 PET/CT imaging, 4-minute static acquisition post-injection, and delayed imaging 3 h post-injection. The imaging results were analysed for lesion count, type, localisation, and maximum standardised uptake values.
[RESULTS] 57.97% exhibited positive findings for pathologic prostatic lesions in the standard PET scans (SUV: 10.24). In contrast, early PET imaging detected lesions in 58.01% of patients (SUV of 5.86), while delayed scans revealed lesions suggestive of malignancy in 55.45% of patients (SUV of 12.79). The analysis demonstrated a statistically significant difference in SUV values across the time points (P < .001). Pathologic lymph nodes on images 60 min p.i. were revealed by an SUV max 60 min p.i.: 15.78; this number for the first 4 min and after 3 h were 7.36, 19.19, respectively. Metastatic bone lesions on WB were found in 38 patients, more than the ESI (n = 37) and DI (n = 24). In comparison, urinary bladder activity assessment was detectable with the WB imaging SUV 60 min 11.07. Even though the SUV max for ESI and DI were 6.95 and 31.97, respectively. In the statistical analysis, pathologic radiotracer uptake in tumour lesions was statistically higher in ESI and WB than in urinary bladder activity.
[CONCLUSIONS] The findings indicate that neither early [68 Ga]Ga-PSMA-11 PET/CT nor delayed imaging significantly enhanced the overall detection rate of malignant lesions in prostate cancer patients. However, the early 4-minute post-injection acquisition of PET images proved beneficial for distinguishing local bladder invasion more effectively.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Prostatic Neoplasms
- Positron Emission Tomography Computed Tomography
- Aged
- Gallium Radioisotopes
- Gallium Isotopes
- Radiopharmaceuticals
- Middle Aged
- Edetic Acid
- Lymphatic Metastasis
- Oligopeptides
- 80 and over
- Time Factors
- Organometallic Compounds
- Cáncer de próstata
- Delayed phase
- Early phase
- Fase estándar
- Fase tardía
- Fase temprana
- Prostate cancer
- Standard phase
- [68 Ga]Ga-PSMA-11 PET/CT scan
… 외 1개
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.